Celltrion Sees ‘Record-High Revenue’ With Increasing Infliximab Sales
As Company Plans To Launch One Biological Product Every Year
South Korea’s Celltrion has delivered a strong fourth quarter in FY21 based on the increase in infliximab sales across all markets as well as a contribution from its Regkirona COVID-19 treatment. The company expects modest top-line growth to continue by launching at least one biological product every year.
